S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.